Results in Children

Jolie,
Real patient. Individual
results may vary.

A Noticeable difference

Caring for your child with uncontrolled moderate-to-severe eczema can be a struggle—especially when you’re constantly trying to avoid triggers. And although your child may outgrow their eczema, approximately 1 in 5 never do.

DUPIXENT in combination with a topical corticosteroid was studied in a 16-week clinical trial with 367 patients ages 6-11 years with severe eczema not adequately controlled with topical prescription treatments.

More children ages 6-11 taking DUPIXENT plus a
topical corticosteroid (TCS) saw clearer skin and less itch.

>2XSaw
Clearer Skin
Greater than 2X as many children taking
DUPIXENT + TCS saw clear or almost clear skin. 30% taking 300 mg dose, every 4 weeks vs 13% on TCS only 39% taking 200 mg dose, every 2 weeks vs 10% on TCS only
~4.5XSaw
Less Itch
Approximately 4.5X as many children taking
DUPIXENT + TCS saw less itch.
54% taking 300 mg dose, every 4 weeks vs 12% on TCS only 61% taking 200 mg dose, every 2 weeks vs 13% on TCS only
Your healthcare provider will tell you how much DUPIXENT to inject and how often.
After an initial loading dose of 2 injections: children 33-66 lb take 300 mg every 4 weeks; children 67-132 lb take 200 mg every 2 weeks.

The safety results of DUPIXENT plus topical corticosteroids observed in children were consistent with what was seen in adults and adolescents with atopic dermatitis. The most common side effects in clinical trial adult patients with atopic dermatitis include injection site reactions, eye and eyelid inflammation, including redness, swelling, and itching, and cold sores in your mouth or on your lips.

View the possible side effects of DUPIXENT in patients with moderate-to-severe eczema (atopic dermatitis).


What You Should Know About the Patients in This Study:

100%
Had severe atopic dermatitis
≈8.5
Average age
≈58%
Average body surface area involvement
≈92%
Had at least one other allergic condition

DUPIXENT Helps Heal the Look and Feel of Skin

In a clinical trial for children ages 6-11, clearer skin was seen. Use the slider to view before and after results of an actual 10-year-old patient and 9-year-old patient after 16 weeks of treatment with DUPIXENT and a topical steroid in a phase 3 clinical trial. A clinical responder was defined as a patient achieving IGA 0 or 1 (clear or almost clear skin). Individual results may vary.

Click and drag
to see results
Click and drag
to see results

GET DOWN TO THE DETAILS

Expand the boxes below to see more detailed results from the clinical study with patients ages 6-11.

Results at 16 weeks when DUPIXENT was taken with topical
corticosteroids (TCS) compared to patients ages 6-11 years on topical corticosteroids only

DUPIXENT 300 mg (<30 kg) with TCS every 4 weeks On topical corticosteroids only

30% saw clear or almost clear skin when DUPIXENT was used with TCS vs 13% on topical corticosteroids only

75% saw at least a 75% skin improvement when DUPIXENT was used with TCS vs 28% on topical corticosteroids only

46% saw at least a 90% skin improvement when DUPIXENT was used with TCS vs 7% on topical corticosteroids only

DUPIXENT 200 mg (≥30 kg) with TCS every 2 weeks On topical corticosteroids only

39% saw clear or almost clear skin when DUPIXENT was used with TCS vs 10% on topical corticosteroids only

75% saw at least a 75% skin improvement when DUPIXENT was used with TCS vs 26% on topical corticosteroids only

36% saw at least a 90% skin improvement when DUPIXENT was used with TCS vs 8% on topical corticosteroids only

Patients ages 6-11 years experienced a significant itch reduction while
participating in a clinical trial

DUPIXENT 300 mg (<30 kg) with TCS every 4 weeks On topical corticosteroids only

54% had significant itch reduction at 16 weeks when DUPIXENT was used with TCS vs 12% on topical corticosteroids only

DUPIXENT 200 mg (≥30 kg) with TCS every 2 weeks On topical corticosteroids only

61% had significant itch reduction at 16 weeks when DUPIXENT was used with TCS vs 13% on topical corticosteroids only

When we started seeing signs of improvement, there were literal tears of joy, and that’s when we knew, like, we were really onto something here.

- Christy (pictured ), caregiver of Jolie,
pediatric patient taking DUPIXENT

Individual results may vary.

MORE PATIENT STORIES
Find a Specialist Who
Treats Eczema

Use this Healthgrades™ tool to easily find nearby
specialists with experience in treating children,
teens, and adults with uncontrolled moderate-to-severe
eczema (atopic dermatitis).

Are you sure you want to leave?
Please note: By clicking on this link, you will be leaving this Sanofi-hosted US website and going to another, entirely independent website. Sanofi US and Regeneron provide these links as a service to its website visitors and users; however, they take no responsibility for the information on any website but their own.
Have an Effective Conversation
With Your Doctor

Our goal is for you or your loved one to get the most out of your visit to the doctor. Fill out our personalized discussion guide to help yourself have a productive conversation during your next visit.


PERSONALIZE YOUR GUIDE

Get the spanish caregiver discussion guide

Download

Get more support

Get exclusive emails, resources, and more support from DUPIXENT MyWay.

Sign Up